Stocktoria
CNS Pharmaceuticals, Inc. CNSP
CNS Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D expense | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $5.1M | $1.9M | $21,267 |
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M | -$9.5M | -$3.8M | -$881,787 |
| Interest expense | — | — | $13,805 | $7,027 | $9,285 | $3,264 | $26,152 | $28,615 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.9M | -$14.9M | -$18.9M | -$15.3M | -$14.5M | -$9.5M | -$3.9M | -$7.4M |
| EPS (diluted) | $-35.75 | $-466.89 | $-12509.11 | $-11.22 | $-16.50 | — | — | — |
| Operating cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M | -$7.3M | -$3.6M | -$716,385 |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M | -$7.3M | -$3.6M | -$716,385 |
| Cash & equivalents | $7.2M | $6.5M | $548,721 | $10.1M | $5.0M | $14.0M | $7.2M | $282,736 |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M | $15.9M | $7.9M | $683,333 |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M | $1.9M | $310,999 | $1.2M |
| Shareholders' equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M | $13.9M | $7.6M | -$549,298 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.